Zhengxing Qu

1.1k total citations
17 papers, 822 citations indexed

About

Zhengxing Qu is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Zhengxing Qu has authored 17 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Zhengxing Qu's work include Monoclonal and Polyclonal Antibodies Research (14 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Glycosylation and Glycoproteins Research (4 papers). Zhengxing Qu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Glycosylation and Glycoproteins Research (4 papers). Zhengxing Qu collaborates with scholars based in United States. Zhengxing Qu's co-authors include David M. Goldenberg, Hans J. Hansen, Rhona Stein, Ivan D. Horak, Susan Chen, Thomas M. Cardillo, Serengulam V. Govindan, Gary L. Griffiths, Victoria Shi and Kristen L. Hess and has published in prestigious journals such as Blood, Cancer and Clinical Cancer Research.

In The Last Decade

Zhengxing Qu

17 papers receiving 799 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhengxing Qu United States 13 465 336 261 230 200 17 822
Julie A. McEarchern United States 13 294 0.6× 537 1.6× 384 1.5× 387 1.7× 189 0.9× 25 1.0k
Heather Horne United States 11 389 0.8× 355 1.1× 198 0.8× 102 0.4× 403 2.0× 31 795
Daming Shan United States 9 507 1.1× 366 1.1× 364 1.4× 292 1.3× 398 2.0× 9 974
Karin Havenith United States 12 207 0.4× 679 2.0× 173 0.7× 122 0.5× 408 2.0× 40 829
Christopher C. Badger United States 15 950 2.0× 366 1.1× 169 0.6× 220 1.0× 452 2.3× 26 1.4k
Olga Ab United States 11 398 0.9× 577 1.7× 73 0.3× 190 0.8× 79 0.4× 23 776
Kimberly H. Harrington United States 11 254 0.5× 492 1.5× 206 0.8× 343 1.5× 55 0.3× 17 807
M. I. Colnaghi Italy 15 402 0.9× 585 1.7× 273 1.0× 487 2.1× 81 0.4× 26 1.1k
Thomas Hawthorne United States 20 226 0.5× 660 2.0× 421 1.6× 274 1.2× 85 0.4× 40 1.2k
Peter Ruf Germany 15 513 1.1× 609 1.8× 369 1.4× 323 1.4× 64 0.3× 30 998

Countries citing papers authored by Zhengxing Qu

Since Specialization
Citations

This map shows the geographic impact of Zhengxing Qu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhengxing Qu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhengxing Qu more than expected).

Fields of papers citing papers by Zhengxing Qu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhengxing Qu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhengxing Qu. The network helps show where Zhengxing Qu may publish in the future.

Co-authorship network of co-authors of Zhengxing Qu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhengxing Qu. A scholar is included among the top collaborators of Zhengxing Qu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhengxing Qu. Zhengxing Qu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Wu, Yaming, Yixian Zhang, Maoliang Wang, et al.. (2013). Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models. Molecular Cancer Therapeutics. 12(4). 427–437. 36 indexed citations
2.
Zhang, Yixian, Stephen Castaneda, Melissa Dumble, et al.. (2011). Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer. Molecular Cancer Therapeutics. 10(12). 2309–2319. 41 indexed citations
3.
Qu, Zhengxing, David M. Goldenberg, Thomas M. Cardillo, et al.. (2007). Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood. 111(4). 2211–2219. 37 indexed citations
4.
Carnahan, Josette, Rhona Stein, Zhengxing Qu, et al.. (2006). Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Molecular Immunology. 44(6). 1331–1341. 138 indexed citations
5.
6.
Rossi, Edmund A., Michele J. Losman, Thomas M. Cardillo, et al.. (2006). Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity.. Blood. 108(11). 2495–2495. 2 indexed citations
7.
Sapra, Puja, Rhona Stein, Zhengxing Qu, et al.. (2005). Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys. Clinical Cancer Research. 11(14). 5257–5264. 127 indexed citations
8.
Qu, Zhengxing, Gary L. Griffiths, William A. Wegener, et al.. (2005). Development of humanized antibodies as cancer therapeutics. Methods. 36(1). 84–95. 40 indexed citations
9.
Rossi, Edmund A., Chien‐Hsing Chang, Michele J. Losman, et al.. (2005). Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells. Clinical Cancer Research. 11(19). 7122s–7129s. 41 indexed citations
10.
Govindan, Serengulam V., Rhona Stein, Zhengxing Qu, et al.. (2004). Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel. Breast Cancer Research and Treatment. 84(2). 173–182. 45 indexed citations
11.
Stein, Rhona, Zhengxing Qu, Thomas M. Cardillo, et al.. (2004). Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 104(12). 3705–3711. 100 indexed citations
12.
13.
Leung, Shui‐on, Zhengxing Qu, H. J. Hansen, et al.. (1999). The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.. PubMed. 5(10 Suppl). 3106s–3117s. 3 indexed citations
14.
Qu, Zhengxing, et al.. (1999). Humanization of Immu31, an alpha-fetoprotein-specific antibody.. PubMed. 5(10 Suppl). 3095s–3100s. 4 indexed citations
15.
Losman, Michele J., Zhengxing Qu, Indira Krishnan, et al.. (1999). Generation and monitoring of cell lines producing humanized antibodies.. PubMed. 5(10 Suppl). 3101s–3105s. 5 indexed citations
16.
Qu, Zhengxing, Robert M. Sharkey, Hans J. Hansen, et al.. (1998). Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates. Journal of Immunological Methods. 213(2). 131–144. 16 indexed citations
17.
Losman, Michele J., Hans J. Hansen, Indira Krishnan, et al.. (1997). Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer. 80(S12). 2660–2666. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie A. McEarchern Breakdown of academic impact, for papers by Heather Horne Breakdown of academic impact, for papers by Daming Shan Breakdown of academic impact, for papers by Karin Havenith Breakdown of academic impact, for papers by Christopher C. Badger Breakdown of academic impact, for papers by Olga Ab Breakdown of academic impact, for papers by Kimberly H. Harrington Breakdown of academic impact, for papers by M. I. Colnaghi Breakdown of academic impact, for papers by Thomas Hawthorne Breakdown of academic impact, for papers by Peter Ruf
Rankless by CCL
2026